2-(2-methyl-1H-imidazol-1-yl)-N-(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}phenyl)-5-(trifluoromethyl)benzenesulfonamide | 1333937-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-methyl-1H-imidazol-1-yl)-N-(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}phenyl)-5-(trifluoromethyl)benzenesulfonamide
• 英文别名: 1-[4-[[2-(2-Methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]sulfonylamino]phenyl]-3-(pyridin-3-ylmethyl)urea
• CAS: 1333937-12-4
• 化学式: C₂₄H₂₁F₃N₆O₃S
• 分子量: 530.53
• InChiKey: NQNBYANPULSIIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• [EN] COMPOUNDS AND THERAPEUTIC USES THEREOF<br/>[FR] COMPOSÉS ET UTILISATIONS THÉRAPEUTIQUES ASSOCIÉES
  申请人：MYREXIS INC

  公开号：WO2011109441A1

  公开（公告）日：2011-09-09

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

  这项发明涉及化合物、药物组合物和方法，用于治疗癌症、全身性或慢性炎症、类风湿关节炎、糖尿病、肥胖、T细胞介导的自身免疫疾病、缺血以及与这些疾病和疾病相关并发症。
• COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Willardsen J. Adam

  公开号：US20150353538A1

  公开（公告）日：2015-12-10

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.
• THERAPEUTIC AND DIAGNOSTIC METHODS
  申请人：Fleischer Tracey C.

  公开号：US20160367541A1

  公开（公告）日：2016-12-22

  The invention relates to methods of treating diseases, particularly cancers, that respond favorably to the inhibition of Nicotinamide phosphoribosyltransferase (Nampt); it also relates to therapeutic methods that utilize Nampt inhibitors in combination with NAD biosynthesis precursors to intentionally kill cancer cells while limiting or minimizing toxicity to normal host cells; and it relates to methods of identifying cancers that will be most responsive to treatment with Nampt inhibitors, particularly when administered in combination with nicotinic acid.
• US8912184B1
  申请人：——

  公开号：US8912184B1

  公开（公告）日：2014-12-16